Life Edit Therapeutics
April Sena, PhD, currently serves as Vice President of Technical Operations at Life Edit Therapeutics, where responsibilities include leading due diligence for potential acquisitions, setting company strategy for innovation, and providing CMC governance. Previously, April held various leadership roles at Seqirus, including Director of Global CMC and Research QA, where April oversaw quality operations for vaccine development and played a key role in the strategic planning and quality decision-making for Covid and influenza vaccines. Earlier experience includes positions at AstraZeneca and the Centers for Disease Control and Prevention, focusing on quality assurance, microbiology, and vaccine research. April earned a PhD in Molecular Genetics and Microbiology and a BS in Biology from Duke University.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.